Cases & Deals

Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®

Clients Genzyme Corporation

Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.